UA95797C2 - Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 - Google Patents
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2Info
- Publication number
- UA95797C2 UA95797C2 UAA200812109A UAA200812109A UA95797C2 UA 95797 C2 UA95797 C2 UA 95797C2 UA A200812109 A UAA200812109 A UA A200812109A UA A200812109 A UAA200812109 A UA A200812109A UA 95797 C2 UA95797 C2 UA 95797C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- growth factor
- vascular endothelial
- receptor type
- tumor therapy
- Prior art date
Links
- 102000009465 Growth Factor Receptors Human genes 0.000 title 1
- 108010009202 Growth Factor Receptors Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 230000008472 epithelial growth Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 238000009175 antibody therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding articles of manufacture and pharmaceutical compositions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06111523 | 2006-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA95797C2 true UA95797C2 (en) | 2011-09-12 |
Family
ID=36540182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200812109A UA95797C2 (en) | 2006-03-22 | 2007-03-20 | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101405030B (en) |
| UA (1) | UA95797C2 (en) |
| ZA (1) | ZA200807764B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3957765B2 (en) * | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | Anti-VEGF antibody |
| ES2245833T5 (en) * | 1998-12-22 | 2013-07-19 | Genentech, Inc. | Antagonists of the cell growth factor of the vascular endothelium and their uses |
-
2007
- 2007-03-20 UA UAA200812109A patent/UA95797C2/en unknown
- 2007-03-20 CN CN2007800099284A patent/CN101405030B/en not_active Expired - Fee Related
-
2008
- 2008-09-09 ZA ZA200807764A patent/ZA200807764B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200807764B (en) | 2009-07-29 |
| CN101405030A (en) | 2009-04-08 |
| CN101405030B (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY151449A (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| CR20240003A (en) | Novel therapeutic delivery moieties and uses thereof | |
| MX2024007356A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof. | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| AR109246A2 (en) | USE OF AN IMMUNOCATE PLAYING UNDERSTANDING AN ANTI-ErbB2 ANTIBODY FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| MX336710B (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases. | |
| EP1765362A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOVASCULAR DISEASES | |
| AR062840A1 (en) | TUMOR THERAPY WITH AN ANTIBODY COMBINATION ANTI RECEIVER OF THE EPIDERMIC GROWTH FACTOR (HER2) | |
| WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| UA94899C2 (en) | Fixed dosing of her antibodies | |
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| JP2017507954A5 (en) | ||
| PH12013500542A1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| MX2011009281A (en) | Antibody drug conjugates (adc) that bind to 24p4c12 proteins. | |
| EA032908B1 (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2008142303A3 (en) | Use of an anti-cxcr4 antibody for treating cancer | |
| CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
| MX2022015375A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer. | |
| UA95797C2 (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| TH93888B (en) | Antibody-based tumor therapy for endothelial proliferation factors And antibodies for the human epithelial proliferation factor of receptor type II. | |
| TH97405B (en) | Tumor cancer therapy with anti-VEGF antibodies | |
| TW200740825A (en) | Cripowellins and synthetic derivatives thereof as medicaments | |
| TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof |